MedTrace Logo

A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

NCT07121244 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-04-13

No results posted yet for this study

Summary

A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.

Conditions

  • Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
  • Metastatic Hormone Receptor Positive Breast Cancer

Interventions

DRUG

68Ga-R11228

68Ga-R11228 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions

DRUG

177Lu-R11228

177Lu-R11228 is a lutetium-labeled small molecule radioligand designed to treat tumor lesions

Sponsors & Collaborators

  • Radionetics Oncology

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2028-06-01
Completion
2033-06-01
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07121244 on ClinicalTrials.gov